One-year results on the safety and efficacy of the InnFocus MicroShunt™ depending on placement and concentration of mitomycin C

• Published in: Journal francais d'ophtalmologie Vol. 38; no. 9; p. 855
• Main Authors: Riss, I, Batlle, J, Pinchuk, L, Kato, Y P, Weber, B A, Parel, J-M
• Format: Journal Article
• Language: French
• Published: France 01-11-2015
• Subjects: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Filtering Surgery - instrumentation; Glaucoma - surgery; Humans; Intraocular Pressure; Middle Aged; Mitomycin - administration & dosage; Retrospective Studies; Time Factors; Tonometry, Ocular; Treatment Outcome; Young Adult; Minimally invasive surgery for glaucoma; Chirurgie du glaucome; Chirurgie filtrante; Filtering surgery; Chirurgie mini-invasive du glaucome; MicroShunt(®); Glaucoma surgery
• ISSN: 1773-0597
• DOI: 10.1016/j.jfo.2015.05.005

To compare intraocular pressure (IOP) at one year with the InnFocus MicroShunt(®) with or without cataract surgery with according to placement and concentration of mitomycin C (MMC) DESIGN: A retrospective two-center, two-surgeon study (France and Dominican Republic).
Adults with POAG requiring filtering surgery. One MicroShunt(®) was placed in one eye of each patient. The effect of concentration and site of application of MMC was assessed by IOP and medication reduction at one year.
Eighty-seven eyes were studied with one-year follow-up. Twenty-three eyes treated with 0.4 mg/mL MMC close to the limbus demonstrated a 55% reduction in IOP from 23.8 ± 5.3 at baseline to 10.7 ± 2.8 mmHg at one year. Topical glaucoma medication/patient was reduced 85% from 2.4 ± 0.9 to 0.3 ± 0.8. Thirty-one eyes treated with 0.2mg/mL MMC close to the limbus demonstrated a 52% reduction in IOP from 27.9 ± 6.7 at baseline to 13.3 ± 3.3 mmHg at one year. Topical glaucoma medication/patient was reduced 88% from 2.5 ± 1.4 to 0.5 ± 1.0. Thirty-three eyes treated with 0.4 mg/mL MMC deep in the pocket demonstrated a 38% reduction in IOP from 25.4 ± 7.9 at baseline to 15.7 ± 4.6 mmHg at one year. Topical glaucoma medication/patient was reduced 72% from 2.9 ± 1.0 to 0.8 ± 1.3. There were no sight-threatening long-term adverse events.
The InnFocus MicroShunt(®) is a filtering surgery whose efficacy is related to the location of application and concentration of MMC used.